: Cystic fibrosis is a life-shortening autosomal recessive disorder caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Small-molecule modulators have substantially improved outcomes in patients with CFTR folding or gating defects. However, individuals carrying class I nonsense mutations or severe class V splicing variants often remain poorly responsive. In these genetic conditions, the main therapeutic limitation is quantitative: there is insufficient CFTR substrate for correctors or potentiators to act effectively. Antisense oligonucleotides (ASOs) are RNA-targeted agents that can increase the pool of CFTR transcripts available for translation by promoting splice correction, inducing exon skipping or selectively modulating nonsense-mediated messenger RNA decay. Although these mechanisms differ, they converge on a common goal: increasing CFTR expression to a functionally relevant and pharmacologically responsive range. This review proposes a threshold-based framework for ASO development in cystic fibrosis. Within this model, ASOs primarily increase CFTR quantity, whereas correctors, potentiators, stabilisers, enhancers and related small molecules improve CFTR quality by acting on folding, trafficking, gating, conductance or membrane stability. The therapeutic aim is not complete molecular normalisation, but functional sufficiency. By raising CFTR abundance above a minimal functional threshold, ASOs may prime selected class I and class V genotypes for subsequent pharmacological modulation and extend precision treatment to patients who currently remain outside the effective range of approved CFTR modulators.
Antisense Oligonucleotides as Quantitative Modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR): A Threshold-Based Therapeutic Framework for Class I and Class V CFTR Mutations
Balestra, Dario;Pinotti, MirkoPenultimo
;
2026
Abstract
: Cystic fibrosis is a life-shortening autosomal recessive disorder caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Small-molecule modulators have substantially improved outcomes in patients with CFTR folding or gating defects. However, individuals carrying class I nonsense mutations or severe class V splicing variants often remain poorly responsive. In these genetic conditions, the main therapeutic limitation is quantitative: there is insufficient CFTR substrate for correctors or potentiators to act effectively. Antisense oligonucleotides (ASOs) are RNA-targeted agents that can increase the pool of CFTR transcripts available for translation by promoting splice correction, inducing exon skipping or selectively modulating nonsense-mediated messenger RNA decay. Although these mechanisms differ, they converge on a common goal: increasing CFTR expression to a functionally relevant and pharmacologically responsive range. This review proposes a threshold-based framework for ASO development in cystic fibrosis. Within this model, ASOs primarily increase CFTR quantity, whereas correctors, potentiators, stabilisers, enhancers and related small molecules improve CFTR quality by acting on folding, trafficking, gating, conductance or membrane stability. The therapeutic aim is not complete molecular normalisation, but functional sufficiency. By raising CFTR abundance above a minimal functional threshold, ASOs may prime selected class I and class V genotypes for subsequent pharmacological modulation and extend precision treatment to patients who currently remain outside the effective range of approved CFTR modulators.I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.


